Stay Ahead of the Curve in Obesity Management: Updates and Advances in 2023

The obesity care community is witnessing rapid evolution, with new therapies, clinical practice guidelines, and models of care emerging every few months. To help clinicians, policymakers, researchers, and other professionals stay updated, the Boston Course in Obesity Medicine is offering a professional education program tailored to 2023.

Highlights of the Past Year in Obesity Science and Clinical Practice

The past year has seen remarkable advancements in obesity science and clinical practice. Some of the key highlights that will be discussed in this year’s program include:

• SURMOUNT-1 Study Results: The first phase 3 study of tirzepatide treatment for obesity, showing an average 22% weight loss.
• STEP TEENS Study Results: The study of semaglutide 2.4 mg weekly for the treatment of obesity in adolescents, demonstrating an average 17% weight loss.
• FDA Approval: Semaglutide 2.4 mg weekly for the treatment of obesity in adolescents.
• New Clinical Practice Guidelines: Publication of the American Academy of Pediatrics’ guidelines for the treatment of obesity in children and adolescents.
• SELECT Study Results: The study of the effect of semaglutide 2.4 mg weekly on cardiovascular outcomes in patients with obesity without diabetes.
• Institute for Clinical and Economic Review Report: The utility and cost-effectiveness of anti-obesity medications.
• New Studies on Weight Loss Mechanisms: Research revealing the body’s resistance to weight loss by calorie reduction alone and the efficacy of GLP-1 receptor agonists in blocking this resistance.
• Studies on Processed Foods and Timed Feeding: The adverse effects of highly processed foods and the benefits and limitations of timed feeding and intermittent fasting.
• Weight-Related Bias and Discrimination: Studies highlighting the negative clinical and psychosocial effects of weight-related bias, stigma, and discrimination.
• New Canadian Clinical Practice Guidelines: Publication of guidelines for obesity evaluation and management.
• Resmetirom Trial Results: The one-year phase 2 trial showing resolution of NASH and improvement in liver fibrosis.
• New Clinical Practice Guidelines for NAFLD and NASH: Multiple new guidelines for the evaluation and management of patients with NAFLD and NASH.
• Landmark Report on Cancer Outcomes: Long-term cancer outcomes after bariatric surgery, revealing substantial improvement in cancer incidence and mortality.
• Metabolic and Bariatric Surgery: Studies demonstrating the benefits of metabolic and bariatric surgery in improving markers of kidney disease.
• Endoscopic Approaches: Studies demonstrating the benefits of endoscopic approaches to treating obesity, diabetes, and NAFLD.
• Combination and Multimodal Treatment: Research highlighting the unique benefits of combination and multimodal treatment of obesity.
• New Models for Efficient Obesity Care: Development of new models for more efficient organization and dissemination of effective obesity care.
• Collaborative Efforts: Emerging collaborative efforts to substantially improve equitable patient access to effective obesity care.
• New Start-up Companies: The emergence of a new cadre of start-up companies aiming to streamline access to effective obesity care.
• Payer and Policymaker Attention: Increasing attention to the substantial clinical and economic benefits of treating obesity effectively as a means of decreasing the number and severity of its medical complications, with a focus on improving reimbursement for obesity treatment.

Program Overview: Obesity Medicine Board Review and Obesity Treatment 2023

Stay ahead of the curve in obesity management with our comprehensive program, covering the latest updates and advances in obesity science and clinical practice.